{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-010273","form_type":"8-K","ticker":"FULC","cik":"0001680581","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2023-01-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.119171+00:00","generated_at":"2026-06-20T14:05:51.935150+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Fulcrum Therapeutics prices upsized public offering of 9.6M shares at $13.00, expected gross proceeds of $125M","bullets":["Offered 9,615,384 shares at $13.00 per share; gross proceeds of $125 million.","Underwriters granted 30-day option to purchase up to an additional 1,442,307 shares.","Net proceeds estimated at $117.3M ($134.9M if option fully exercised).","Goldman Sachs, SVB Securities, Piper Sandler acting as joint book-running managers.","Offering expected to close on January 20, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-010273","json":"https://secwatch.observer/filing/0001193125-23-010273.json","markdown":"https://secwatch.observer/filing/0001193125-23-010273.md","text":"https://secwatch.observer/filing/0001193125-23-010273.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000119312523010273/0001193125-23-010273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000119312523010273/d451832d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T14:05:51.935150+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eb2ff3502e3c3c2800838b8edb0b9b2afdff64d4","claim":"Fulcrum Therapeutics, Inc. entered into underwriting agreement with Goldman Sachs & Co. LLC, SVB Securities LLC and Piper Sandler & Co., as representatives of the several underwriters valued at approximately $117.3 million (effective 2023-01-17).","evidence_excerpt":"On January 17, 2023, Fulcrum Therapeutics, Inc., or Fulcrum, entered into an underwriting agreement with Goldman Sachs & Co. LLC, SVB Securities LLC and Piper Sandler & Co., as the representatives of the several underwriters, or the Underwriters, relating to an underwritten public offering of 9,615,384 shares of its common stock, par value $0.001 per share, at a price to the public of $13.00 per share, less underwriting discounts and commissions.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680581/000119312523010273/0001193125-23-010273-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Goldman Sachs & Co. LLC, SVB Securities LLC and Piper Sandler & Co., as representatives of the several underwriters"},{"label":"Value","value":"approximately $117.3 million"},{"label":"Effective","value":"2023-01-17"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}